Adenosine triphosphate (ATP) is released into the extracellular environment during transplantation, and acts via purinergic receptors to amplify the alloimmune response. Here, using a well-established murine model of allogeneic corneal transplantation, we investigated the immunomodulatory mechanisms of the purinergic receptor antagonist oxidized ATP (oATP). Corneal transplantation was performed using C57BL/6 donors and BALB/c hosts. oATP or sterile saline was administered via intraperitoneal injection for 2 weeks postoperatively. Frequencies of CD45 + leukocytes, CD11b + MHCII + antigen presenting cells (APCs), CD4 + IFN-γ + effector Th1 cells and CD4 + Foxp3 + regulatory t cells (Tregs) were evaluated by flow cytometry. Slit-lamp microscopy was performed weekly for 8 weeks to evaluate graft opacity and determine transplant rejection. Treatment with oATP was shown to significantly reduce graft infiltration of CD45 + leukocytes, decrease APC maturation and suppress effector Th1 cell generation relative to saline-treated control. No difference in Treg frequencies or Foxp3 expression was observed between the oATP-treated and control groups. Finally, oATP treatment was shown to reduce graft opacity and increase graft survival. This report demonstrates that oATP limits the alloimmune response by regulating APC maturation and suppressing the generation of alloreactive Th1 immunity.
Results
Inhibition of the purinergic pathway with oATP reduces corneal infiltration of leukocytes and suppresses APC maturation. To investigate the effect of treatment with oATP on corneal infiltration of immune cells, graft recipients received intraperitoneal injection of oATP postoperatively and tissues were collected ( Fig. 1A) . Saline-treated animals served as controls. Flow cytometric data demonstrated an increase in corneal infiltration of CD45 + leukocytes in saline-treated animals, which was substantially reduced in the oATPtreated group (Fig. 1B) . Similarly, the frequencies of MHCII + CD11b + mature APCs were significantly reduced in the oATP-treated group following transplantation, as compared to the saline-treated group (Fig. 1C ). Having observed that treatment with oATP resulted in lower frequencies of mature APCs at the graft site, we investigated whether oATP also inhibited maturation of APCs in the DLNs. Our data demonstrate that treatment with oATP abrogates the increased frequencies of CD11b + MHCII + cells in the DLNs of saline-treated mice following transplantation ( Fig. 1D ).
Treatment with oATP suppresses CD4 + effector T cell generation and graft infiltration.
During the alloimmune response, the inflammatory microenvironment at the cornea results in the acquisition of MHCII and co-stimulatory molecules by local APCs 8 . These mature APCs egress from the graft site via lymphatic vessels to the DLNs, where they prime naïve T cells by presenting alloantigens, resulting in the expansion and differentiation of a population of IFN-γ-secreting CD4 + Th1 cells 8 . In our study, we sought to establish whether the decreased frequencies of CD11b + MHCII + APCs observed in the DLNs of oATP-treated mice resulted in decreased frequencies of effector T cells. Consistent with our previous publications, we observed a significant increase in CD4 + IFN-γ + Th1 cells in the DLNs following transplantation in the saline-treated group 27, 31 . Notably, this phenomenon was abrogated in the oATP-treated hosts ( Fig. 2A ). Indeed, evaluation of CD4 + cell infiltration in the cornea revealed a similar pattern, with amplified frequencies in the saline-treated group compared to naïve mice, but with oATP treatment decreasing the CD4 + cell frequencies to baseline (Fig. 2B ). Having observed that treatment with oATP both reduced frequencies of mature APCs and IFN-γ-secreting CD4 + Th1 cells following corneal transplantation, we examined whether oATP had a direct effect on T cells, or whether the decreased frequencies of Th1 cells observed were secondary to the inhibitory effect of oATP on APCs. Our in vitro mixed lymphocyte reactions using APCs derived from C57BL/6 mice and T cells from BALB/c mice indicate that, in addition to its APC-mediated immunoregulatory activity, oATP has a direct effect on alloreactive T cells. Indeed, treatment of T cells with oATP resulted in a 34% reduction in dilution of CFSE-labeled cells, compared with a 64% reduction when APCs were treated with oATP, and a 74% reduction when both T cells and oATP were treated with oATP ( Fig. S1 ). oATP treatment does not promote the significant expansion of regulatory T cell frequencies following corneal transplantation. In order to evaluate the effect of oATP treatment on Tregs, we harvested DLNs following transplantation and analyzed single cell suspensions by flow cytometry (Fig. 1A) . No difference in the frequencies of CD4 + Foxp3 + Tregs was detected between naïve mice, saline-treated allograft recipients and oATP-treated allograft recipients ( Fig. 3A) . Moreover, Foxp3 expression levels were similar between the saline-and oATP-treated hosts (median fluorescence intensity [MFI] equal to 43 and 40 respectively). As with the lymph node data, corneal single cell suspensions derived from saline-and oATP-treated groups showed similar frequencies of CD4 + Foxp3 + cells and levels of Foxp3 expression (MFI equal to 28 and 27 respectively; Fig. 3B ). The functional relevance of Foxp3 expression as a marker of Treg suppressive activity in transplantation has been demonstrated in previous work by our laboratory 12 . Nevertheless, we conducted additional in vitro Treg functional assays, in which treatment of Tregs with oATP was not observed to result in a substantial reduction in T cell proliferation as compared to PBS-treated Tregs (Fig. S2 ).
Treatment with oATP decreases graft opacity and promotes corneal allograft survival. Finally,
we investigated the effect of oATP treatment on graft opacity and transplant survival. Graft opacity was assessed by slit lamp microscopy once weekly for eight weeks (as depicted in Fig. 4A ), and graft survival was determined as previously described [27] [28] [29] [30] . The oATP-treated transplanted group exhibited significantly lower graft opacity scores compared to the saline-treated group from postoperative week 4 onwards ( Fig. 4B ). A concomitant increase in the survival of the grafts in oATP-treated recipients, relative to saline-treated controls, was observed ( Fig. 4C ).
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Discussion
The activation of purinergic P2X and P2Y receptors by extracellular ATP amplifies inflammation 13, 15, 16 . This study advances our understanding of the immunoregulatory capacities of periodate-oxidized ATP, an irreversible antagonist of ATP, in the setting of corneal allotransplantation. Specifically, our data show that following corneal www.nature.com/scientificreports www.nature.com/scientificreports/ grafting, treatment with oATP: (1) reduces corneal infiltration of leukocytes and suppresses APC maturation; (2) decreases frequencies of Th1 cells in draining lymphoid tissue, as well as graft-infiltrating CD4 + T cells; and (3) increases corneal transplant survival.
Tissue damage resulting from allotransplantation triggers the release of ATP either from necrotic cells or via pannexin channels in activated immune cells and apoptotic cells 17 . APCs are known to express purinergic receptors, including P2X 7 R and P2Y 2 R, that when activated upregulate the expression of MHCII and co-stimulatory molecules 14 . In our study, we demonstrate that blockade of the purinergic pathway with oATP results in a reduction of mature APCs at both the graft site and draining lymphoid tissues (Fig. 1C,D) . Notably, the oATP-mediated suppression of APC maturation in the setting of allotransplantation has not previously been reported [20] [21] [22] . However, in a model of renal ischemia-reperfusion injury, Koo and colleagues have demonstrated that systemic treatment with oATP prior to ischemia-reperfusion injury results in decreased frequencies of mature APCs in the kidney compared to saline-treated controls 23 . By suppressing APC maturation in corneal allotransplantation, oATP limits the priming of naïve T cells.
After priming by APCs, naïve T cells differentiate into CD4 + IFNγ + Th1 effectors, the principal mediators of acute corneal graft rejection 8, 10 . Our data demonstrate a significant increase in the frequencies of CD4 + IFNγ + cells in the DLNs of saline-treated allograft recipients, but this effect is fully abrogated by treatment with oATP ( Fig. 2A) . In a study using a murine model of cardiac transplantation, Vergani and colleagues reported that treatment with oATP promotes cardiac transplant survival in 80% of murine recipients of a fully mismatched allograft (C57BL/6 recipients of BALB/c donor hearts) 21 . Furthermore, the authors describe reduced numbers of IFN-γ-producing cells in spleens harvested from oATP-treated mice compared to untreated controls, with a difference between the groups that was maintained at day 100 post-transplantation 21 . Similar findings have been reported in a murine model of islet allograft rejection 20 . These studies are consistent with our data, suggesting that treatment with oATP suppresses the Th1 alloimmune response. It is interesting to note that in Vergani and colleagues' cardiac transplant study 21 , as well as in other studies of lung 22 and islet transplantation 20 , short-term systemic treatment with oATP was demonstrated to improve long-term graft survival. We also observed that 14 days' treatment with oATP promoted transplant survival at 8 weeks, suggesting that by suppressing the acute phase of the alloimmune response, oATP has enduring effects on allograft survival. www.nature.com/scientificreports www.nature.com/scientificreports/ There has been some controversy in the literature regarding the effect of systemic oATP on Tregs. Liu and colleagues report significantly reduced numbers of Tregs in lung allografts from oATP-treated animals as compared to vehicle controls 22 . In contrast, using a model of renal ischemia-reperfusion injury, Koo and colleagues attribute the therapeutic function of oATP to the expansion of regulatory T cells 23 . Here, the investigators observed frequencies of CD4 + Foxp3 + T cells in the kidneys of oATP-treated mice more than four times greater than those detected in the vehicle control group. However, in a mouse model of cardiac transplantation, Vergani and colleagues report no difference in peripheral Treg frequencies between oATP-treated animals and vehicle controls, but observed a significant increase in Treg frequencies in oATP-treated animals at 100 days post-transplantation 21 . Moreover, a study conducted by the same group on islet transplantation demonstrated no difference between oATP-treated animals and vehicle controls following transplantation 20 .
Given the critical role of Tregs in limiting the alloimmune response in corneal transplantation 11, 12 , in our study we investigated the effect of systemic oATP treatment on Treg frequencies both at the cornea and draining lymphoid tissues. Our data show no significant difference CD4 + Foxp3 + Treg frequencies either at the graft site or DLNs (Fig. 3) . Foxp3 expression is known to reflect the functional status of Tregs in allotransplantation 12 . However, our data do not reveal a significant difference in Foxp3 expression (MFI) between oATP-treated and saline-treated animals.
The purpose of this study was not to conduct a comprehensive survey of immune cells modulated by oATP, and it is conceivable that oATP promotes graft survival by suppressing a variety of different pro-inflammatory cells. Indeed, previous studies have demonstrated a direct effect of oATP on T cells (i.e. independent of APCs), which may partially account for the decreased frequencies of pathogenic T cells and improved allograft survival observed in our study 24, 26 . Yet the work of our group 29, 32, 33 and others 31, [34] [35] [36] [37] has established that in our murine model of corneal transplantation, the activation of CD11b + MHCII + cells and subsequent infiltration of graft-attacking CD4 + T cells plays a critical role in determining immune rejection. Our previous studies have established that 14 days post-transplantation is an optimum time point to evaluate the alloimmune response prior to the onset of graft rejection [38] [39] [40] , yet it is feasible that kinetic analysis of immune cell frequencies and activation may have captured additional immunomodulatory effects of oATP. Indeed, we have observed substantial suppression of APC maturation as early as day 3 post-transplantation in mice treated with oATP compared to PBS control (Fig. S3 ).
Our data evaluating graft survival demonstrate that treatment with oATP significantly reduces corneal graft opacity and promotes transplant survival compared to saline-treated controls (Fig. 4) . Taken together, our findings strongly suggest that oATP promotes allograft survival by suppressing the effector arm of the alloimmune response. Moreover, our data imply that limiting the Th1 response with oATP treatment may be a viable therapeutic strategy to promote the survival of corneal allografts.
Methods
Animals. Six Corneal transplantation. Allogeneic orthotopic corneal transplantation was performed as described previously [27] [28] [29] [30] . Briefly, 2 mm diameter donor buttons were excised from the central cornea of C57BL/6 mice using scissors (Vannas; Storz Instruments, San Dimas, CA). BALB/c host beds were prepared by excising a 1.5 mm diameter button from the central cornea. The donor button was then secured into position on the recipient bed via 8 interrupted 11-0 nylon sutures (AB-0550S, MANI, Tochigi, Japan). Tarsorrhaphy was performed with a single 8-0 suture (AB-2056, MANI, Tochigi, Japan) to close the eyelid until post-operative day 3. Corneal sutures were removed at post-operative day 7. The surgical procedures were performed using intraperitoneal ketamine (120 mg/kg bodyweight) and xylazine (20 mg/kg bodyweight) for anesthesia. Furthermore, buprenorphine (0.1 mg/kg bodyweight) was administered intraoperatively and every 8-12 hours postoperatively (up to 48 hours) as analgesia.
Evaluation of graft survival. Graft survival was assessed for 8 weeks using a slit-lamp biomicroscope. Graft opacity was scored on a weekly basis according to an established scoring system (range, 0-5+); with immune rejection defined by a score of 2+ for two consecutive examinations (i.e. a level of opacity that obscures iris details) [27] [28] [29] [30] 41 . To exclude grafts undergoing primary failure, those grafts with scores 2+ at post-operative day 14 were excluded from experimentation and analysis. oATP treatment protocol. oATP (250 μg, Sigma Aldrich, St. Louis, MO) diluted in 100 μl sterile saline was administered via intraperitoneal (i.p.) injection once daily for the 14 days following grafting (Fig. 1A) , based on the treatment schedule in previously published transplantation studies [20] [21] [22] . The first dose of oATP was administered intraoperatively, at the time of transplantation. The control group was administered daily i.p. injections of 100 μl sterile saline.
Isolation of corneal cells and lymph node cell preparation.
Collagenase digestion was used to prepare single-cell suspensions from the corneal samples, as described previously 27, 42 . Briefly, corneas were digested in RPMI media (Lonza, Walkersville, MD) containing 2 mg/ml DNase I (Roche, Basel, Switzerland) and 2 mg/ ml collagenase type IV (Sigma-Aldrich, St. Louis, MO) for 60 min at 37 °C. Following this, samples were filtered
